A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

2011 • 2,267 citations

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

2004 • 1,810 citations

A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer

2007 • 1,562 citations

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

2008 • 1,102 citations

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

2007 • 941 citations

AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity

2011 • 921 citations

Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)

2001 • 868 citations

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

1997 • 811 citations

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

2009 • 789 citations

Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

2012 • 533 citations

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

2011 • 524 citations

Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235

2008 • 485 citations

Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling

2008 • 283 citations

Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation of Smad4(Dpc4) Immunostaining With Pattern of Disease Progression

2011 • 278 citations

Targeted cancer therapies

2010 • 223 citations

Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy

2011 • 207 citations

Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer

2010 • 200 citations

HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer

2001 • 150 citations

Dose-finding in phase I clinical trials based on toxicity probability intervals

2007 • 119 citations

Integrating Molecular Mechanisms and Clinical Evidence in the Management of Trastuzumab Resistant or Refractory HER-2+ Metastatic Breast Cancer

2011 • 69 citations

Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors.

2011 • 19 citations